FWFenglei Wu

Fenglei Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fenglei Wu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Nan Hu

    Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People’s Hospital of Lianyungang

    7 shared publications
  • Yidong Hong

    Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People’s Hospital of Lianyungang

    6 shared publications
  • Jingzhou Zhang

    Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People’s Hospital of Lianyungang

    5 shared publications
  • Kangjie Zhou

    Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang

    5 shared publications
  • Chenxi Mao

    Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People’s Hospital of Lianyungang

    3 shared publications
  • Luming Zhao

    Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People’s Hospital of Lianyungang

    3 shared publications

Latest Publications

  • Open Access

    Multiscale characterization of an inflammatory macrophage state associated with an air pollutant–prioritized prognostic signature in gastric cancer

    by Luming Zhao, Nan Hu, Yimeng Xu, Chenxi Mao, Yidong Hong, Jingzhou Zhang, Kangjie Zhou, Fenglei Wu

    Background: Air pollutants are implicated in carcinogenesis, but their relevance to gastric cancer (GC) across prognosis, tumor organization and cell behavior remains unclear. We integrated evidence to evaluate pollutant-prioritized GC candidates. Methods: Seven pollutants were integrated with GeneCards/OMIM GC genes using toxicology and candidate-prioritization resources. Robustness analyses used alternative disease definitions, Fisher’s tests, 5,000 degree- and annotation-matched null sets, enrichment and protein–protein interaction networks. TCGA-STAD supported nested evaluation of 117 survival pipelines and a five-gene neural network, with locked external testing in GSE84437 and GSE54129. Single-cell, donor-aware macrophage, CellChat, Monocle2, multiplex immunofluorescence and cell2location-guided Visium analyses resolved tissue context. Docking, 100-ns molecular dynamics and bibliometrics examined GSK-3β-centered hypotheses. AGS cells underwent benzene/toluene dose screening followed by CCK-8, colony formation, Transwell and wound-healing assays. Results: Among 176 genes, 63 overlapped with GC beyond matched-null expectations (empirical P = 0.012), with enrichment in inflammation, hypoxia, apoptosis, metabolism and carcinogenesis. APRGSig (DNMT1, GSK3B, HNF4A, MMP9 and TERT) remained associated with overall survival after age/T/N/M adjustment (HR per 1-SD increase, 2.31; 95% CI, 1.98–2.71) and achieved a locked external C-index of 0.701; exploratory GC-ANN achieved an external AUC of 0.962. Score-defined APRGSig-high macrophages showed broader predicted crosstalk, whereas donor-aware analysis identified an inflammatory/stress-associated MALAT1-high state. Multiplex immunofluorescence provided representative compartment-level localization of APRGSig-encoded proteins; four Visium sections showed directionally consistent positive spatial concordance between APRGSig scores and inferred MALAT1-high abundance. Formal GSK-3β–benzene/toluene models yielded Vina scores of −7.1/−7.4 kcal/mol and remained numerically persistent over 100 ns; bibliometrics of 311 publications highlighted proliferation, invasion and metastasis. At 2.5 mM benzene and 20 μM toluene, both exposures increased AGS clonogenic capacity, Matrigel traversal and wound closure (all P < 0.05). Conclusions: This framework integrates predictive, tissue-resolved, structural and phenotype-level evidence to prioritize exposure-linked molecular and immune hypotheses in GC.

  • Open Access

    Integrative single-cell, spatial, and bulk transcriptomics reveal an FMR1–FTO axis linked to the immune-excluded phenotype in gastric cancer

    by Chenxi Mao, Miao Zhang, Kangjie Zhou, Yidong Hong, Yiqian Han, Luming Zhao, Mingtong Liang, Jingzhou Zhang, Nan Hu, Fenglei Wu

    Background: Immune exclusion is a major barrier to immune checkpoint inhibitor (ICI) efficacy in gastric cancer, yet the spatial mechanisms by which m 6 A regulators drive this phenotype remain unclear. Methods: We integrated single-cell RNA-seq, spatial transcriptomics, and functional assays to map the gastric cancer microenvironment and derived an m 6 A regulator score to quantify the spatial coupling between m 6 A patterns and immune exclusion. Results: CAFs emerged as a central hub that excluded T cells via collagen–integrin interactions and MIF signaling, forming a CAF-defined collagen barrier that impeded CD8 + T-cell entry into the tumor core. In immune-excluded samples, m 6 A regulator scores were selectively elevated in tumor nests compared with surrounding stroma. Across five bulk transcriptomic datasets, this phenotype was associated with reduced predicted ICI responsiveness, activation of chemotherapy resistance programs, and poor survival. Mechanistically, FTO was highly expressed in the immune-excluded phenotype and correlated with stromal activation and T-cell exclusion. Serial immunohistochemistry and multiplex immunofluorescence revealed high FMR1 protein expression in immune-excluded tumors, with CD8 + T cells largely confined to the stroma. Cycloheximide (CHX) chase and MG132 treatment showed that FMR1 depletion reduced FTO protein abundance and accelerated FTO turnover in an MG132-sensitive manner, consistent with a post-translational regulatory relationship. Conclusions: Collectively, our data support an FMR1–FTO module associated with the immune-excluded phenotype and nominate this axis as a potential vulnerability for disrupting stromal immune barriers. The FMR1–FTO axis may represent a candidate target for strategies aimed at relieving immune exclusion and improving immunotherapy sensitivity.


  • Open Access

    Fragile X mental retardation 1 gene FMR1 promotes proliferation, migration, and invasion of gastric cancer cells via c-MYC

    by Yiqian Han, Chenxi Mao, Kangjie Zhou, Mingtong Liang, Luming Zhao, Yidong Hong, Jingzhou Zhang, Nan Hu, Fenglei Wu

    Background: Gastric cancer is a highly aggressive malignancy with poor prognosis and low survival rates. The Fragile X Mental Retardation 1 (FMR1) gene has been implicated in the development and progression of various tumors, but its role in gastric cancer remains unclear. Methods: We performed pan-cancer expression analysis of FMR1 using the TIMER2.0 platform, and evaluated its differential expression in gastric cancer versus normal gastric tissues in the TCGA cohort. FMR1 expression was validated by qRT-PCR, Western blotting, and immunohistochemistry. Using R software and clinical samples to evaluate the association between FMR1 expression levels and clinicopathological factors in gastric cancer patients, and to analyze patient survival curves. The relationship between FMR1 expression and tumor immune infiltration was analyzed via the TISIDB database, and after co-culture, cytokine secretion by CD4⁺ T cells was assessed using ELISA following FMR1 knockdown in tumor cells. Functional enrichment analyses of FMR1 and its interacting genes were performed. Single-cell transcriptomics was used to extend the interpretation of intratumoral lineages and states. Malignant epithelial populations were identified using inferCNV, and these cells were subsequently stratified by FMR1 expression for GSVA. We measured FMR1 expression in control and FMR1 knockdown gastric cancer cells, performed proliferation, migration, and invasion assays to investigate the biological effects of FMR1 in gastric cancer. Mechanistic insights were further explored through co-immunoprecipitation, cycloheximide chase, proteasome inhibition, and rescue assays. Results: FMR1 was significantly overexpressed in gastric cancer tissues compared to normal gastric mucosa, with high expression levels associated with poor prognosis. The differential expression of FMR1 in gastric cancer was strongly associated with the activity of multiple immune cell types within the tumor microenvironment. Functional assays further demonstrated that FMR1 knockdown suppressed cytokine secretion by CD4⁺ T cells. The expression level of FMR1 in malignant epithelial cells is higher than that in the non—malignant group, and the high—expression group of FMR1 in malignant cells shows a consistent increase in the Hallmark gene sets directly related to stem cell like phenotype, chemotherapy resistance, and immune evasion. Knockdown of FMR1 suppressed gastric cancer cell proliferation, migration, and invasion, while mechanistic studies indicated that FMR1 positively regulates c-MYC expression to drive these phenotypes. And we found that FMR1 interacted with c-MYC at the protein level and stabilized c-MYC by suppressing its proteasomal degradation. Conclusion: Our findings demonstrate that FMR1 promotes gastric cancer cell proliferation, migration, and invasion through c-MYC signaling, suggesting that FMR1 may serve as a potential prognostic biomarker and therapeutic target for gastric cancer.


  • Open Access

    Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment

    by Ziting Zhang, You Ji, Nan Hu, Qinqi Yu, Xinrui Zhang, Jie Li, Fenglei Wu, Huae Xu, Qiyun Tang, Xiaolin Li


  • Enhanced antitumor effect of icariin nanoparticles coated with iRGD functionalized erythrocyte membrane

    by You Ji, Ziting Zhang, Wenjun Hou, Min Wu, Haisi Wu, Nan Hu, Mengnan Ni, Chunming Tang, Fenglei Wu, Huae Xu


  • Open Access

    An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas

    by Kangjie Zhou, Nan Hu, Yidong Hong, Xueyu Wu, Jingzhou Zhang, Huan Lai, Yang Zhang, Fenglei Wu

    This study aimed to explore an immune response-related gene signature to predict the clinical prognosis and tumor immunity of stomach adenocarcinomas (STAD). Based on the expression and clinical data of STAD in the TCGA database, the immune cell infiltration status was evaluated using CIBERSORT and ESTIMATE methods. Samples were grouped into “hot” and “cold” tumors based on immune cell infiltration status and consensus clustering. The infiltration abundance of activated memory CD4 T cells and CD8 T cells had a significant effect on the overall survival of STAD patients. Among the three clusters, cluster 2 had a higher immune score and a significantly higher abundance of CD8 T cells and activated memory CD4 T cells were assigned as a hot tumor, while cluster 1 and 3 were assigned as a cold tumor. DEGs between hot and cold tumors were mainly enriched in immune-related biological processes and pathways. Total of 13 DEGs were related to the overall survival (OS). After the univariate and multivariable Cox regression analysis, three signature genes (PEG10, DKK1, and RGS1) was identified to establish a prognostic model. Patients with the high-risk score were associated with worse survival, and the risk score had an independent prognostic value. Based on TIMER online tool, the infiltration levels of six immune cell types showed significant differences among different copy number statuses of PEG10, DKK1, and RGS1. In this study, an immune-related prognostic model containing three genes was established to predict survival for STAD patients.


  • Open Access

    A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer

    by Nan Hu, Wei Li, Yidong Hong, Zengtao Zeng, Jingzhou Zhang, Xueyu Wu, Kangjie Zhou, Fenglei Wu


  • Open Access

    Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine

    by Nan Hu, Jun Feng Yin, Ze Ji, Yidong Hong, Puyuan Wu, Baoxiang Bian, Ziyan Song, Rutian Li, Qin Liu, Fenglei Wu

    Background/Aims: MicroRNA-21 is an oncogenic miR (oncomiR) frequently elevated in gastric cancer (GC). Overexpression of miR-21 decreases the sensitivity of GC cells to 5-fluorouridine (5-Fu) and trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Receptor-mediated endocytosis plays a crucial role in the delivery of biotherapeutics including anti-miRNA oligonucleotides (AMOs). This study is a continuation of earlier findings involving poly(ε-caprolactone) (PCL)-poly (ethylene glycol) (PEG) nanoparticles (PEG-PCL NPs), which were coated with trastuzumab to target GC with HER2 receptor over-expression using anti-miRNA-21 (AMO-21) and 5-Fu. Methods: HER-PEG-PCL NPs were prepared by one-step carbodiimide coupling using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAc) and Sulfo-NHS in aqueous phase. Covalent coupling of amino groups at the surface of PEG-PCL with the carboxyl groups of trastuzumab was analyzed by X-ray photoelectron spectroscopy (XPS). AMO-21/5-Fu NPs were formulated by a double-emulsion solvent evaporation technique. The cell line specificity, cellular uptake and AMO-21 delivery were investigated through the rhodamine-B-labeled 6-carboxyfluorescein (FAM)-AMO-21-PEG-PCL NPs coated with or without the antibody in both Her2-positive (NUGC4) and negative GC cells (SGC7901) visualized by fluorescence microscopy. The cytotoxicity of the HER-PEG-PCL NPs encapsulating AMO-21 was evaluated by MTT and apoptosis. Real-time reverse-transcription polymerase chain reaction (RT-PCR) was used to examine miR-21 and phosphatase and tensin homolog (PTEN) and Sprouty2 expression in GC cell lines. The antitumor effects of AMO-21/5-Fu NPs were compared with other groups in xenograft gastric cancer mice. Results: The antibody conjugates significantly enhanced the cellular uptake of NPs. The AMO-21/5-Fu NPs effectively suppressed the target miRNA expression in GC cells, which further up-regulated PTEN and Sprouty2. As a result, the sensitivity of HER2-expressing gastric cancer to trastuzumab and 5-Fu were enhanced both in vitro and in vivo. The approach enhanced the targeting by trastuzumab as well as antibody-dependent cellular cytotoxicity (ADCC) of immune effector cells Conclusions: Taken together, the results provide insight into the biological and clinical potential of targeted AMO-21 and 5-Fu co-delivery using modified trastuzumab for GC treatment.


  • Open Access

    Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon

    by Yi-Dong Hong, Jian Zhang, Ming Zhuang, Wei Li, Puy-Uan Wu, Ru-Tian Li, Nan Hu, Bao-Xiang Bian, Zi-Yan Song, Feng-Lei Wu

    Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon